Long-term cardiac composite risk following adjuvant treatment in breast cancer patients
- Author:
Hong Bae CHOI
1
;
Sangchul YUN
;
Sung Woo CHO
;
Min Hyuk LEE
;
Jihyoun LEE
;
Suyeon PARK
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Heart diseases; Chemotherapy; Adjuvant; Echocardiography
- MeSH: Anthracyclines; Breast Neoplasms; Breast; Cardiomyopathy, Dilated; Cardiotoxicity; Drug Therapy; Echocardiography; Follow-Up Studies; Heart Diseases; Humans; Medical Records; Radiotherapy; Retrospective Studies; Taxoids
- From: Korean Journal of Clinical Oncology 2018;14(2):102-107
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Cardiotoxicity is a serious late complication of breast cancer treatment. Individual treatment risk of specific drugs has been investigated. However, studies on the evaluation of the composite risk of chemotherapeutic agents are limited.METHODS: We retrospectively analyzed the medical records of breast cancer patients who received adjuvant treatment and had available serial echocardiography results. Patients were assigned to subgroups based on chemotherapy containing anthracyclines (A), anthracyclines and taxanes (A+T), and radiotherapy (RT). The development of cardiac disease and serial ejection fraction (EF) were reviewed. EF decline up to 10% from baseline was considered grade 1 cardiotoxicity and EF decline >20% or absolute value < 50% was considered grade 2 cardiotoxicity. The most recent medical records and echocardiography results over 1 year of chemotherapy completion were also reviewed. Late cardiotoxicity was defined as a lack of recovery of EF decline or aggravated EF decline from baseline.RESULTS: In total, 123 patients were evaluated. A small reduction in EF was observed after chemotherapy in both chemotherapy groups. There were no significant differences between groups A and A+T in EF decline following chemotherapy. We could not find any differences in composite risk between the chemotherapy groups and the RT group during follow-up. Late cardiotoxicity was seen in 15.45% of patients. During follow-up, three patients were diagnosed with dilated cardiomyopathy.CONCLUSION: There was no significant composite risk elevation following adjuvant treatment of breast cancer. However, late cardiotoxicity was considerable and further research in this direction is necessary.
